Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

about

3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

P2860

Q55435176-0C76DE35-577C-4A7C-8B9C-00877E1000F4 Q55436995-05800E23-3C8C-47BA-89CF-57A8BD8563F7

P2860

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

Item

http://www.wikidata.org/entity/Q47174470

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@en

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@nl

type

Item

label

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@en

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@nl

prefLabel

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@en

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@nl

P1476

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

@en

P2093

Diana G Iacob

http://www.w3.org/2001/XMLSchema#string

Simona A Iacob

http://www.w3.org/2001/XMLSchema#string

P2860

CCR5 monoclonal antibodies for HIV-1 therapy

HIV-1 entry inhibitors: an overview

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

Monoclonal antibody-based therapies for microbial diseases

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

P304

2323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3389/FMICB.2017.02323

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29230203

http://www.w3.org/2001/XMLSchema#string

P932

5711820

http://www.w3.org/2001/XMLSchema#string

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

about

P2860

P2860

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932